GleamWall
中文EN

ZYBT Zhengye Biotechnology Holding Ltd Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1975641

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-12.0%
TTM net income YoY-64.0%
TTM EPS YoY-63.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin49.0%
Operating margin8.8%
Net margin6.1%
FCF margin14.7%
EBITDA margin21.8%

Returns

ROE4.1%
ROA2.3%
ROIC (approx.)5.0%
Asset turnover0.38x

Leverage & solvency

Liabilities / assets28.5%
Debt / equity0.04x
Current ratio1.31x
Interest coverage4.07x

Cash quality & payout

Operating cash flow / net income3.63x
Accruals ratio-6.0%
Payout ratio141.7%
Capex / revenue7.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31 · USDFY20242024-12-31 · CNY
Income statement
Revenue$16.64M186.36M
Cost of revenue$13.23M95.06M
Gross profit$3.41M91.30M
R&D expense$2.58M12.79M
SG&A expense$4.43M22.57M
Operating income-$10.08M16.44M
Interest expense$486,0004.04M
Pretax income-$10.28M14.39M
Income tax$1.59M924,000
Net income-$9.98M11.31M
EBITDA-$6.38M40.60M
EPS (basic)—0.25
EPS (diluted)—0.25
Weighted avg. shares (diluted)47.35M45.67M
Balance sheet
Cash & equivalents$7.20M18.61M
Short-term investments$223,0001.43M
Receivables$2.64M59.56M
Inventory$5.60M58.22M
Current assets$19.65M177.57M
PP&E, net$33.86M255.16M
Intangibles$6.73M14.85M
Total assets$62.41M493.25M
Current liabilities$17.23M135.91M
Short-term debt$100,0007.19M
Long-term debt$1.37M4.80M
Total debt$1.47M11.99M
Total liabilities$18.56M140.71M
Shareholders' equity$35.72M283.96M
Net debt-$5.73M-6.62M
Shares outstanding—45.67M
Cash flow statement
Operating cash flow$1.91M41.05M
Capital expenditure$144,00013.59M
Free cash flow$1.77M27.46M
Investing cash flow-$1.81M-27.66M
Financing cash flow$4.62M-22.13M
Depreciation & amortization$3.70M24.16M
Dividends paid—16.02M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.